155 related articles for article (PubMed ID: 11766619)
1. Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.
Cardiovasc J S Afr; 2001; 12(4):242-3. PubMed ID: 11766619
[No Abstract] [Full Text] [Related]
2. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
[TBL] [Abstract][Full Text] [Related]
3. Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.
Cardiovasc J S Afr; 2001; 12(4):240-1. PubMed ID: 11766617
[No Abstract] [Full Text] [Related]
4. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.
Croom KF; Curran MP; Goa KL; Perry CM
Drugs; 2004; 64(9):999-1028. PubMed ID: 15101793
[TBL] [Abstract][Full Text] [Related]
5. [Evidence based treatment of diabetic nephropathy].
Sugimoto T
Nihon Rinsho; 2002 Oct; 60 Suppl 10():294-300. PubMed ID: 12430244
[No Abstract] [Full Text] [Related]
6. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
Palmer AJ; Valentine WJ; Ray JA
Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
[TBL] [Abstract][Full Text] [Related]
7. [Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].
de Alvaro F
Nefrologia; 2001; 21 Suppl 3():76-82. PubMed ID: 11642211
[No Abstract] [Full Text] [Related]
8. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
MMW Fortschr Med; 2001 Aug; 143(31-32):44. PubMed ID: 11556191
[No Abstract] [Full Text] [Related]
10. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
[TBL] [Abstract][Full Text] [Related]
11. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
[TBL] [Abstract][Full Text] [Related]
12. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
[TBL] [Abstract][Full Text] [Related]
13. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
14. [Health economic aspects of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Schute LL
Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1448; author reply 1448. PubMed ID: 15213879
[No Abstract] [Full Text] [Related]
15. EC approves irbesartan for the treatment of diabetic renal disease.
Cardiovasc J S Afr; 2002; 13(4):216-7. PubMed ID: 12402931
[No Abstract] [Full Text] [Related]
16. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
[TBL] [Abstract][Full Text] [Related]
17. Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Ruilope LM
Am J Hypertens; 1997 Dec; 10(12 Pt 2):325S-331S. PubMed ID: 9438777
[TBL] [Abstract][Full Text] [Related]
18. Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
Ann Intern Med; 2003 Apr; 138(7):I43. PubMed ID: 12667050
[No Abstract] [Full Text] [Related]
19. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
20. How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics.
Llewelyn DE; Garcia-Puig J
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):141-5. PubMed ID: 15526250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
